This agent is being studied as an adjunct to NAC therapy for acetaminophen poisoning because of its ability to reduce oxidant stress?
Calmangafodipir reduces oxidative stress and therefore is postulated to potentially prevent acetaminophen-induced hepatotoxicity. In one open-label study, calmangafodipir, when combined with NAC, had no safety concerns or increase in adverse events. Further studies are needed to determine if indeed there is a therapeutic benefit.
Morrison EE. Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 hour regimen of NAC for paracetamol overdose (POP). doi: doi.org/10.1016/j.ebiom.2019.07.013